HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results Highlights of the second quarter include:
to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share increased
– HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its second quarter ended July 31, 2026.
"HealthEquity delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity. "These results reflect strong execution across the business and the durability of our model as growth comes from more places, member relationships deepen and technology-enabled efficiency improves how we serve members and clients. This momentum gives us confidence to raise fiscal 2027 guidance and enter the second half focused on scaling efficiently and creating long-term value."
Revenue for the second quarter ended July 31, 2026 was $350.7 million, an increase of 8% compared to $325.8 million for the second quarter ended July 31, 2025. Revenue this quarter included: service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million.
Net income was $65.6 million, or $0.78 per diluted share, for the second quarter ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for the second quarter ended July 31, 2025. Net income margin was 19% for the second quarter ended July 31, 2026, compared to 18% for the second quarter ended July 31, 2025.
Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per diluted share, for the second quarter ended July 31, 2025.
Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026, an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31, 2025.
New HSAs from sales were 202 thousand, an increase of 24% compared to the second quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an increase of 8% year over year, including 0.9 million HSAs with investments, an increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8 million, including 7.0 million complementary CDBs.
Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of July 31, 2026.
The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program. 1
For the fiscal year ending January 31, 2027, management is raising guidance and now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $628 million to $636 million.
See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.
HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time) on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.
To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.
• Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non- operating items.
• Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future 2 efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
• our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
• our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
• the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;
• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
• the significant competition we face and may face in the future, including from those with greater resources than us;
• our reliance on the availability and performance of our technology and communications systems;
• potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
• our reliance on partners and third-party vendors for distribution and important services;
• our ability to develop and implement updated features for our technology platforms and communications systems; and
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward- looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
(in thousands, except par January 31, value) July 31, 2026 2026 ────────────────────────────────────────────────────────────────────────────── -unaudited Assets Current assets Cash and cash $ 256,003 $ 318,927 equivalents Accounts receivable, net of allowance for doubtful accounts of $1,067 and 122,193 123,696 $924 as of July 31, 2026 and January 31, 2026, respectively Prepaid expenses and 82,008 69,658 other current assets Total current 460,204 512,281 assets Property and equipment, 4,823 3,177 net Operating lease 32,874 36,310 right-of-use assets Intangible 1,047,797 1,097,172 assets, net Goodwill 1,648,145 1,648,145 Other assets 77,520 83,247 Total assets $ 3,271,363 $ 3,380,332 Liabilities and stockholders’ equity Current liabilities Accounts $ 8,592 $ 12,159 payable Accrued 37,913 60,392 compensation Accrued 97,300 74,388 liabilities Operating lease 9,970 9,911 liabilities Total current 153,775 156,850 liabilities Long-term liabilities Long-term debt, net of 931,062 957,379 issuance costs Operating lease 29,984 34,190 liabilities, non-current Other long-term 73,999 31,007 liabilities Deferred tax 92,433 93,710 liability Total long-term 1,127,478 1,116,286 liabilities Total 1,281,253 1,273,136 liabilities Commitments and contingencies Stockholders’ equity Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares — — issued and outstanding as of July 31, 2026 and January 31, 2026, respectively Common stock, $0.0001 par value, 900,000 shares authorized, 82,909 and 85,007 8 8 shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively Additional paid-in 1,896,571 1,916,989 capital Accumulated 162,583 195,906 earnings Accumulated other -69,052 -5,707 comprehensive loss Total stockholders’ 1,990,110 2,107,196 equity Total liabilities and $ 3,271,363 $ 3,380,332 stockholders’ equity
(in thousands) Cash flows from Six months ended operating July 31, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 135,062 $ 113,769 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 80,169 77,195 amortization Stock-based 41,616 33,404 compensation Amortization of debt discount and 558 533 issuance costs Amortization of gains on -168 — derivatives Deferred taxes 19,321 30,711 Changes in operating assets and liabilities: Accounts 1,503 6,842 receivable, net Prepaid expenses and other current -12,581 -20,650 and non-current assets Operating lease right-of-use 3,436 3,339 assets Accrued -21,095 -35,032 compensation Accounts payable, accrued liabilities, -13,595 -3,785 and other current liabilities Operating lease liabilities, -4,206 -3,951 non-current Other long-term 3,665 -1,771 liabilities Net cash provided by operating 233,685 200,604 activities Cash flows from investing activities: Capitalized software -30,720 -26,464 development costs Purchases of property and -1,340 -859 equipment Settlement of -7,759 — derivatives, net Net cash used in investing -39,819 -27,323 activities Cash flows from financing activities: Repurchases of -231,054 -125,810 common stock Principal payments -26,875 -50,000 on long-term debt Settlement of client-held funds 480 596 obligation, net Proceeds from exercise of common 659 10,446 stock options Net cash used in financing -256,790 -164,768 activities Increase (decrease) in cash -62,924 8,513 and cash equivalents Beginning cash and 318,927 295,948 cash equivalents Ending cash and $ 256,003 $ 304,461 cash equivalents
(in thousands) Six months ended July Supplemental cash 31, flow data: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Interest expense $ 23,350 $ 28,362 paid in cash Income tax payments, 35,586 6,507 net Supplemental disclosures of non-cash investing and financing activities: Capitalized software development costs included in accounts 3,434 3,380 payable, accrued liabilities, or accrued compensation Purchases of property and equipment 1,294 155 included in accounts payable or accrued liabilities Repurchases of common stock 3,255 1,246 included in accrued liabilities Exercise of common stock options 57 — receivable
Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:
The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2026:
(1) Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July 31, 2026.
Outlook for the year ending (in millions) January 31, 2027 ────────────────────────────────────────────────────────────────────────────── Net income $242 - 248 Interest income -7 Interest expense 50 Income tax provision 81 - 83 Depreciation and amortization 54 Amortization of acquired intangible assets 104 Stock-based compensation expense 87 Merger integration expenses 5 Amortization of incremental costs to obtain a 9 contract Costs associated with unused office space 3 Adjusted EBITDA $628 - 636
(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. 10 Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
Outlook for the year ending (in millions, except per share data) January 31, 2027 ────────────────────────────────────────────────────────────────────────────── Net income $242 - 248 Income tax provision 81 - 83 Income before income taxes - GAAP 323 - 331 Non-GAAP adjustments: Amortization of acquired intangible assets 104 Stock-based compensation expense 87 Merger integration expenses 5 Costs associated with unused office space 3 Total adjustments to income before income taxes - 199 GAAP Income before income taxes - Non-GAAP 522 - 530 Income tax provision - Non-GAAP (1) 131 - 133 Non-GAAP net income $392 - 398 Diluted weighted-average shares 84 GAAP net income per diluted share $2.88 - 2.96 Non-GAAP net income per diluted share $4.66 - 4.73
(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. 11
Term Definition Health Savings Account, which is a financial account through which HSA consumers spend and save long-term for healthcare on a tax-advantaged basis. Consumer-directed benefits offered by employers, including flexible spending and health reimbursement CDB arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits. HSA member Consumers with HSAs that we serve. HSA members’ custodial cash assets held by our federally insured depository partners and our insurance Total HSA Assets company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner. Client Our employer clients. Total Accounts The sum of HSAs and CDBs on our platforms. Deposits held on behalf of our Client-held funds Clients to facilitate administration of our CDBs. Our health plan partners, benefits Network Partner administrators, and retirement plan recordkeepers. Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, Adjusted EBITDA acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, Non-GAAP net income acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. Non-GAAP net income per diluted Calculated by dividing non-GAAP net share income by diluted weighted-average shares outstanding.
Full text with the tables
HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
Highlights of the second quarter include:
• Net income increased
10%
to $65.6 million , and net income margin increased to
19%
from
18%
last year.
• Adjusted EBITDA increased
11%
to $167.0 million , and Adjusted EBITDA margin increased to
48%
from
46%
last year.
• Revenue increased
8%
to $350.7 million .
• Net income per diluted share rose
15%
to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share
increased
15%
to $1.24 .
• Total HSA Assets grew
14%
to $37.9 billion .
• Returned $108.1 million to shareholders through stock repurchases.
Draper, Utah – August 27, 2026
– HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the
largest independent health savings account ("HSA") custodian by account volume
and a leader in consumer-directed benefits ("CDBs"), today announced financial
results for its second quarter ended July 31, 2026.
"HealthEquity delivered a record-setting second quarter, with record Adjusted
EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets
of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity.
"These results reflect strong execution across the business and the durability
of our model as growth comes from more places, member relationships deepen and
technology-enabled efficiency improves how we serve members and clients. This
momentum gives us confidence to raise fiscal 2027 guidance and enter the second
half focused on scaling efficiently and creating long-term value."
Second quarter financial results
Revenue for the second quarter ended July 31, 2026 was $350.7 million, an
increase of 8% compared to $325.8 million for the second quarter ended July 31,
2025. Revenue this quarter included: service revenue of $124.4 million,
custodial revenue of $175.9 million, and interchange revenue of $50.4 million.
Net income was $65.6 million, or $0.78 per diluted share, for the second quarter
ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for
the second quarter ended July 31, 2025. Net income margin was 19% for the second
quarter ended July 31, 2026, compared to 18% for the second quarter ended July
31, 2025.
Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the
second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per
diluted share, for the second quarter ended July 31, 2025.
Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026,
an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted
EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31,
2025.
Account and asset metrics
New HSAs from sales were 202 thousand, an increase of 24% compared to the second
quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an
increase of 8% year over year, including 0.9 million HSAs with investments, an
increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8
million, including 7.0 million complementary CDBs.
Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year
over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion
of HSA investments. Client-held funds, which are deposits held on behalf of our
Clients to facilitate administration of our CDBs, and from which we generate
custodial revenue, were $0.9 billion as of July 31, 2026.
Stock repurchase program
The Company repurchased 1.2 million shares of its common stock for $108.1
million during the second quarter ended July 31, 2026. As of July 31, 2026,
$948.4 million of common stock remained authorized for repurchase under the
stock repurchase program.
1
Business outlook
For the fiscal year ending January 31, 2027, management is raising guidance and
now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net
income is between $242 million and $248 million, resulting in net income of
$2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income,
calculated using the method described below, is between $392 million and $398
million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73
(based on an estimated 84 million diluted weighted-average shares outstanding).
Management expects Adjusted EBITDA of $628 million to $636 million.
See “Non-GAAP financial information” below for definitions of our Adjusted
EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial
measures used throughout this release to the most comparable GAAP financial
measures is included with the financial tables at the end of this release.
Conference call
HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time)
on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial
results. The conference call will be accessible by dialing 1-833-630-1956, or
1-412-317-1837 for international callers, and referencing conference ID
"HealthEquity." A live audio webcast of the call will be available on the
investor relations section of our website at http://ir.healthequity.com.
Non-GAAP financial information
To supplement our financial information presented on a GAAP basis, we disclose
non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and
non-GAAP net income per diluted share.
• Adjusted EBITDA is earnings before interest, taxes, depreciation and
amortization, amortization of acquired intangible assets, stock-based
compensation expense, merger integration expenses, acquisition costs, gains and
losses on equity securities, amortization of incremental costs to obtain a
contract, costs associated with unused office space, and certain other non-
operating items.
• Non-GAAP net income is calculated by adding back to GAAP net income before
income taxes the following items: amortization of acquired intangible assets,
stock-based compensation expense, merger integration expenses, acquisition
costs, gains and losses on equity securities, costs associated with unused
office space, and losses on extinguishment of debt, and subtracting a non-GAAP
tax provision using a normalized non-GAAP tax rate.
• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net
income by diluted weighted-average shares outstanding.
Non-GAAP financial measures should be considered in addition to results prepared
in accordance with GAAP and should not be considered as a substitute for, or
superior to, GAAP results. We believe that these non-GAAP financial measures
provide useful information to management and investors regarding certain
financial and business trends relating to the Company's financial condition and
results of operations. The Company cautions investors that non-GAAP financial
information, by its nature, departs from GAAP; accordingly, its use can make it
difficult to compare current results with results from other reporting periods
and with the results of other companies. In addition, while amortization of
acquired intangible assets is being excluded from non-GAAP financial measures,
the revenue generated from those acquired intangible assets is not excluded.
Whenever we use these non-GAAP financial measures, we provide a reconciliation
of the applicable non-GAAP financial measure to the most closely applicable GAAP
financial measure. Investors are encouraged to review the related GAAP financial
measures and the reconciliation of the non-GAAP financial measures to their most
directly comparable GAAP financial measure as detailed in the tables below.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed
benefits for more than 17 million accounts in partnership with employers,
benefits advisors, and health and retirement plan providers who share our
mission to save and improve lives by empowering healthcare consumers. For more
information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act of
1995, including but not limited to, statements regarding our industry, business
strategy, plans, goals and expectations concerning our markets and market
position, product expansion, future operations, expenses and other results of
operations, revenue, margins, profitability, acquisition synergies, future
2
efficiencies, tax rates, capital expenditures, liquidity and capital resources
and other financial and operating information. When used in this discussion, the
words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,”
“estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,”
“future” and the negative of these or similar terms and phrases are intended to
identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future
events, results or outcomes. These expectations may or may not be realized.
Although we believe the expectations reflected in the forward-looking statements
are reasonable, we can give you no assurance these expectations will prove to be
correct. Some of these expectations may be based upon assumptions, data or
judgments that prove to be incorrect. Actual events, results and outcomes may
differ materially from our expectations due to a variety of known and unknown
risks, uncertainties and other factors. Although it is not possible to identify
all of these risks and factors, they include, among others, risks related to the
following:
• our ability to adequately place and safeguard our custodial assets, or the
failure of any of our depository or insurance company partners;
• our ability to compete effectively in a rapidly evolving healthcare and
benefits administration industry;
• our dependence on the continued availability and benefits of tax-advantaged
HSAs and other CDBs;
• the impact of fraudulent account activity involving our member accounts or our
third-party service providers on our reputation and financial results;
• our ability to successfully identify, acquire and integrate additional
portfolio purchases or acquisition targets;
• the significant competition we face and may face in the future, including from
those with greater resources than us;
• our reliance on the availability and performance of our technology and
communications systems;
• potential future cybersecurity breaches of our technology and communications
systems and other data interruptions, including resulting costs and liabilities,
reputational damage and loss of business;
• the current uncertain healthcare environment, including changes in healthcare
programs and expenditures and related regulations;
• our ability to comply with current and future privacy, healthcare, tax, ERISA,
investment adviser and other laws applicable to our business;
• our reliance on partners and third-party vendors for distribution and
important services;
• our ability to develop and implement updated features for our technology
platforms and communications systems; and
• our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the
risks detailed in our filings with the Securities and Exchange Commission,
including, without limitation, our Annual Report on Form 10-K for the fiscal
year ended January 31, 2026 and subsequent periodic and current reports. Past
performance is not necessarily indicative of future results. We undertake no
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. Forward-
looking statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.
Investor Relations Contact
Richard Putnam
801-727-1000
[email protected]
3
HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in
thousands,
except par January 31,
value) July 31, 2026 2026
──────────────────────────────────────────────────────────────────────────────
-unaudited
Assets
Current
assets
Cash and cash $ 256,003 $ 318,927
equivalents
Accounts
receivable,
net of
allowance
for doubtful
accounts of
$1,067 and 122,193 123,696
$924
as of July
31, 2026 and
January 31,
2026,
respectively
Prepaid
expenses and 82,008 69,658
other current
assets
Total current 460,204 512,281
assets
Property and
equipment, 4,823 3,177
net
Operating
lease 32,874 36,310
right-of-use
assets
Intangible 1,047,797 1,097,172
assets, net
Goodwill 1,648,145 1,648,145
Other assets 77,520 83,247
Total assets $ 3,271,363 $ 3,380,332
Liabilities
and
stockholders’
equity
Current
liabilities
Accounts $ 8,592 $ 12,159
payable
Accrued 37,913 60,392
compensation
Accrued 97,300 74,388
liabilities
Operating
lease 9,970 9,911
liabilities
Total current 153,775 156,850
liabilities
Long-term
liabilities
Long-term
debt, net of 931,062 957,379
issuance
costs
Operating
lease 29,984 34,190
liabilities,
non-current
Other
long-term 73,999 31,007
liabilities
Deferred tax 92,433 93,710
liability
Total
long-term 1,127,478 1,116,286
liabilities
Total 1,281,253 1,273,136
liabilities
Commitments
and
contingencies
Stockholders’
equity
Preferred
stock,
$0.0001 par
value,
100,000
shares
authorized,
no shares — —
issued and
outstanding
as of July
31,
2026 and
January 31,
2026,
respectively
Common stock,
$0.0001 par
value,
900,000
shares
authorized,
82,909 and
85,007 8 8
shares issued
and
outstanding
as of July
31, 2026 and
January 31,
2026,
respectively
Additional
paid-in 1,896,571 1,916,989
capital
Accumulated 162,583 195,906
earnings
Accumulated
other -69,052 -5,707
comprehensive
loss
Total
stockholders’ 1,990,110 2,107,196
equity
Total
liabilities
and $ 3,271,363 $ 3,380,332
stockholders’
equity
4
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations (unaudited)
(in
tho… Three Six
exc… mont… mon…
per ended end…
sha… July July
dat… 31, 31,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Ser… $ 124,… $ 117,… $ 247… $ 237,…
rev…
Cus… 175,… 159,… 350… 316,…
rev…
Int… 50,3… 48,0… 107… 102,…
rev…
Tot… 350,… 325,… 705… 656,…
rev…
Cost
of
rev…
Ser… 73,1… 75,1… 151… 163,…
cos…
Cus… 12,0… 11,1… 23,… 21,8…
cos…
Int… 7,525 6,947 15,… 14,7…
cos…
Tot…
cost 92,7… 93,2… 191… 199,…
of
rev…
Gro… 257,… 232,… 514… 456,…
pro…
Ope…
exp…
Sal…
and 23,2… 19,9… 50,… 45,9…
mar…
Tec…
and 73,9… 64,8… 141… 126,…
dev…
Gen…
and 34,8… 29,9… 66,… 55,5…
adm…
Amo…
of
acq… 26,2… 27,0… 52,… 54,0…
int…
ass…
Mer… 971 1,266 2,0… 2,541
int…
Tot…
ope… 159,… 142,… 312… 284,…
exp…
Inc…
from 98,6… 89,6… 201… 172,…
ope…
Oth…
exp…
Int… -12,… -14,… -25… -29,…
exp…
Oth…
inc… 1,780 3,391 3,8… 6,124
net
Tot…
oth… -10,… -11,… -21… -23,…
exp…
Inc…
bef… 87,8… 78,0… 180… 149,…
inc…
tax…
Inc…
tax 22,2… 18,1… 45,… 35,2…
pro…
Net $ 65,6… $ 59,8… $ 135… $ 113,…
inc…
Net
inc…
per
sha…
Bas… $ 0.79 $ 0.69 $ 1.61 $ 1.31
Dil… $ 0.78 $ 0.68 $ 1.60 $ 1.29
Wei…
num…
of
sha…
used
in
com…
net
inc…
per
sha…
Bas… 83,3… 86,5… 83,… 86,6…
Dil… 84,0… 87,7… 84,… 88,1…
5
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of comprehensive income (unaudited)
Thr… Six
mon… mont…
end… ended
July July
(in 31, 31,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 65,6… $ 59,8… $ 135,… $ 113…
inc…
Oth…
com…
inc…
(lo…
Cash
flow
hed…
Net
unr… -37,… 203 -63,… 203
gai…
(lo…
Rec…
of
net
(ga…
los… 22 — -126 —
inc…
in
net
inc…
Net
cha…
net
of
inc…
tax
ben…
(ex… -37,… 203 -63,… 203
of
$12…
$(7…
$20…
and
$(7…
res…
Tot…
oth…
com… -37,… 203 -63,… 203
inc…
(lo…
Com… $ 28,3… $ 60,0… $ 71,7… $ 113…
inc…
6
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
(in thousands)
Cash flows from Six months ended
operating July 31,
activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 135,062 $ 113,769
Adjustments to
reconcile net
income to
net cash provided
by operating
activities:
Depreciation and 80,169 77,195
amortization
Stock-based 41,616 33,404
compensation
Amortization of
debt discount and 558 533
issuance costs
Amortization of
gains on -168 —
derivatives
Deferred taxes 19,321 30,711
Changes in
operating assets
and
liabilities:
Accounts 1,503 6,842
receivable, net
Prepaid expenses
and other current -12,581 -20,650
and
non-current assets
Operating lease
right-of-use 3,436 3,339
assets
Accrued -21,095 -35,032
compensation
Accounts payable,
accrued
liabilities, -13,595 -3,785
and other current
liabilities
Operating lease
liabilities, -4,206 -3,951
non-current
Other long-term 3,665 -1,771
liabilities
Net cash provided
by operating 233,685 200,604
activities
Cash flows from
investing
activities:
Capitalized
software -30,720 -26,464
development costs
Purchases of
property and -1,340 -859
equipment
Settlement of -7,759 —
derivatives, net
Net cash used in
investing -39,819 -27,323
activities
Cash flows from
financing
activities:
Repurchases of -231,054 -125,810
common stock
Principal payments -26,875 -50,000
on long-term debt
Settlement of
client-held funds 480 596
obligation, net
Proceeds from
exercise of common 659 10,446
stock
options
Net cash used in
financing -256,790 -164,768
activities
Increase
(decrease) in cash -62,924 8,513
and cash
equivalents
Beginning cash and 318,927 295,948
cash equivalents
Ending cash and $ 256,003 $ 304,461
cash equivalents
7
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
(in thousands) Six months ended July
Supplemental cash 31,
flow data: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Interest expense $ 23,350 $ 28,362
paid in cash
Income tax payments, 35,586 6,507
net
Supplemental
disclosures of
non-cash
investing and
financing
activities:
Capitalized software
development costs
included in accounts 3,434 3,380
payable, accrued
liabilities, or
accrued compensation
Purchases of
property and
equipment 1,294 155
included in accounts
payable or accrued
liabilities
Repurchases of
common stock 3,255 1,246
included in
accrued liabilities
Exercise of common
stock options 57 —
receivable
Stock-based compensation expense (unaudited)
Total stock-based compensation expense included in the condensed consolidated
statements of operations and comprehensive income is as follows:
Thr… Six
mon… mont…
end… ended
July July
(in 31, 31,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cost
of $ 2,713 $ 3,114 $ 5,500 $ 6,5…
rev…
Sal…
and 3,229 1,529 7,753 6,3…
mar…
Tec…
and 6,178 5,732 10,1… 11,…
dev…
Gen…
and 10,0… 8,693 18,2… 8,8…
adm…
Tot…
sto… $ 22,2… $ 19,0… $ 41,6… $ 33,…
com…
exp…
Total Accounts (unaudited)
(in
thous… July July January
except 31, 31, % 31,
perce… 2026 2025 Change 2026
──────────────────────────────────────────────────────────────────────────────
HSAs 10,739 9,989 8 % 10,570
New
HSAs
from 202 163 24 % 553
sales
-
Quart…
New
HSAs
from 374 312 20 % 1,040
sales
-
Year-…
New
HSAs
from — — * —
acqui…
-
Year-…
HSAs
with 939 782 20 % 832
inves…
CDBs 7,016 7,153 -2 % 7,221
Total 17,755 17,142 4 % 17,791
Accou…
Avera…
Total
Accou… 17,710 17,044 4 % 17,462
-
Quart…
Avera…
Total
Accou… 17,772 17,083 4 % 17,220
-
Year-…
* Not meaningful
HSA Assets (unaudited)
(in
mil… July July Janu…
exc… 31, 31, % 31,
per… 2026 2025 Chan… 2026
──────────────────────────────────────────────────────────────────────────────
HSA $ 17,3… $ 17,0… 2 % $ 17,982
cash
HSA 20,5… 16,1… 28 % 18,482
inv…
Tot…
HSA 37,9… 33,1… 14 % 36,464
Ass…
Ave…
dai…
HSA 17,3… 17,0… 2 % 17,090
cash
-
Qua…
Ave…
dai…
HSA 17,5… 17,1… 2 % 17,082
cash
-
Yea…
8
HSA cash maturity schedule
The following table summarizes the amount of HSA cash held by our depository
partners and insurance company partners that is expected to reprice by fiscal
year and the respective average annualized yield currently earned on that HSA
cash as of July 31, 2026:
Year ending
January 31, (in
billions, except Average annualized
percentages) HSA cash expected yield
Remainder of 2027 2.3 to reprice 1.5 %
──────────────────────────────────────────────────────────────────────────────
2028 2.5 4.0 %
2029 1.8 3.8 %
2030 2.3 4.4 %
Thereafter 7.8 4.4 %
Total (1) $ 16.7 3.9 %
(1) Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July
31, 2026.
Client-held funds (unaudited)
(in
mill… July July January
exce… 31, 31, % 31,
perc… 2026 2025 Change 2026
──────────────────────────────────────────────────────────────────────────────
Clie… $ 931 $ 818 14 % $ 1,090
funds
Aver…
daily
Clie… 936 884 6 % 879
funds
-
Quar…
Aver…
daily
Clie… 986 893 10 % 864
funds
-
Year…
Reconciliation of net income to Adjusted EBITDA (unaudited)
Three Six
mont… mon…
ended end…
July July
(in 31, 31,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 65,6… $ 59,8… $ 135… $ 113,…
inc…
Int… -1,7… -3,3… -3,… -6,0…
inc…
Int… 12,6… 14,9… 25,… 29,8…
exp…
Inc…
tax 22,2… 18,1… 45,… 35,2…
pro…
Dep…
and 15,6… 11,4… 27,… 23,1…
amo…
Amo…
of
acq… 26,2… 27,0… 52,… 54,0…
int…
ass…
Sto…
com… 22,2… 19,0… 41,… 33,4…
exp…
Mer…
int… 971 1,266 2,0… 2,541
exp…
Amo…
of
inc…
cos… 2,139 1,951 4,2… 3,877
to
obt…
a
con…
Cos…
ass…
with 1,016 723 1,7… 1,575
unu…
off…
spa…
Oth… -20 -27 -181 -27
Adj… $ 166,… $ 151,… $ 331… $ 291,…
EBI…
Net income and Adjusted EBITDA as a percentage of revenue (unaudited)
… …
… …
… …
… …
… $ % …
… … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … … % … $ … …
… % … % … %
$ … $ … $ … … % … $ … …
… % … % … %
9
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
Outlook for the year ending
(in millions) January 31, 2027
──────────────────────────────────────────────────────────────────────────────
Net income $242 - 248
Interest income -7
Interest expense 50
Income tax provision 81 - 83
Depreciation and amortization 54
Amortization of acquired intangible assets 104
Stock-based compensation expense 87
Merger integration expenses 5
Amortization of incremental costs to obtain a 9
contract
Costs associated with unused office space 3
Adjusted EBITDA $628 - 636
Note: Values presented may not calculate due to rounding.
Reconciliation of net income to non-GAAP net income (unaudited)
(in Three Six
tho… mont… mon…
exc… ended end…
per July July
sha… 31, 31,
dat… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 65,6… $ 59,8… $ 135… $ 113,…
inc…
Inc…
tax 22,2… 18,1… 45,… 35,2…
pro…
Inc…
bef…
inc… 87,8… 78,0… 180… 149,…
tax…
-
GAAP
Non…
adj…
Amo…
of
acq… 26,2… 27,0… 52,… 54,0…
int…
ass…
Sto…
com… 22,2… 19,0… 41,… 33,4…
exp…
Mer…
int… 971 1,266 2,0… 2,541
exp…
Cos…
ass…
with 1,016 723 1,7… 1,575
unu…
off…
spa…
Tot…
adj…
to
inc…
bef… 50,4… 48,0… 98,… 91,5…
inc…
tax…
-
GAAP
Inc…
bef…
inc… 138,… 126,… 278… 240,…
tax…
-
Non…
Inc…
tax
pro… 34,5… 31,5… 69,… 60,1…
-
Non…
(1)
Non…
net 103,… 94,5… 208… 180,…
inc…
Dil…
wei… 84,0… 87,7… 84,… 88,1…
sha…
GAAP
net
inc… $ 0.78 $ 0.68 $ 1.60 $ 1.29
per
dil…
sha…
Non…
net
inc… $ 1.24 $ 1.08 $ 2.47 $ 2.05
per
dil…
sha…
(1) The Company utilizes a normalized non-GAAP tax rate to provide better
consistency across the interim reporting periods within a given fiscal year by
eliminating the effects of non-recurring and period-specific items, which can
vary in size and frequency, and which are not necessarily reflective of the
Company’s longer-term operations. The normalized non-GAAP tax rate applied to
each period presented was 25%. The Company may adjust its non-GAAP tax rate as
additional information becomes available and in conjunction with any other
significant events occurring that may materially affect this rate, such as
merger and acquisition activity, changes in business outlook, or other changes
in expectations regarding tax regulations.
10
Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
Outlook for the year ending
(in millions, except per share data) January 31, 2027
──────────────────────────────────────────────────────────────────────────────
Net income $242 - 248
Income tax provision 81 - 83
Income before income taxes - GAAP 323 - 331
Non-GAAP adjustments:
Amortization of acquired intangible assets 104
Stock-based compensation expense 87
Merger integration expenses 5
Costs associated with unused office space 3
Total adjustments to income before income
taxes - 199
GAAP
Income before income taxes - Non-GAAP 522 - 530
Income tax provision - Non-GAAP (1) 131 - 133
Non-GAAP net income $392 - 398
Diluted weighted-average shares 84
GAAP net income per diluted share $2.88 - 2.96
Non-GAAP net income per diluted share $4.66 - 4.73
Note: Values presented may not calculate due to rounding.
(1) The Company utilizes a normalized non-GAAP tax rate to provide better
consistency across the interim reporting periods within a given fiscal year by
eliminating the effects of non-recurring and period-specific items, which can
vary in size and frequency, and which are not necessarily reflective of the
Company’s longer-term operations. The normalized non-GAAP tax rate applied to
each period presented was 25%. The Company may adjust its non-GAAP tax rate as
additional information becomes available and in conjunction with any other
significant events occurring that may materially affect this rate, such as
merger and acquisition activity, changes in business outlook, or other changes
in expectations regarding tax regulations.
11
Certain terms
Term Definition
Health Savings Account, which is a
financial account through which
HSA consumers spend and save long-term
for healthcare on a tax-advantaged
basis.
Consumer-directed benefits offered by
employers, including flexible
spending and health reimbursement
CDB arrangements (“FSAs” and “HRAs”),
Consolidated Omnibus Budget
Reconciliation Act (“COBRA”)
administration, commuter and other
benefits.
HSA member Consumers with HSAs that we serve.
HSA members’ custodial cash assets
held by our federally insured
depository partners and our insurance
Total HSA Assets company partners. Total HSA Assets
also includes HSA members'
investments held by our custodial
investment fund partner.
Client Our employer clients.
Total Accounts The sum of HSAs and CDBs on our
platforms.
Deposits held on behalf of our
Client-held funds Clients to facilitate administration
of our CDBs.
Our health plan partners, benefits
Network Partner administrators, and retirement plan
recordkeepers.
Earnings before interest, taxes,
depreciation and amortization,
amortization of acquired intangible
assets, stock-based compensation
expense, merger integration expenses,
Adjusted EBITDA acquisition costs, gains and losses
on equity securities, amortization of
incremental costs to obtain a
contract, costs associated with
unused office space, and certain
other non-operating items.
Calculated by adding back to GAAP net
income before income taxes the
following items: amortization of
acquired intangible assets,
stock-based compensation expense,
merger integration expenses,
Non-GAAP net income acquisition costs, gains and losses
on equity securities, costs
associated with unused office space,
and losses on extinguishment of debt,
and subtracting a non-GAAP tax
provision using a normalized non-GAAP
tax rate.
Non-GAAP net income per diluted Calculated by dividing non-GAAP net
share income by diluted weighted-average
shares outstanding.
12